GlassScriptPhysician profile
Natalia E Almodovar Arbelo
NPI 1114381902
$8,870.74
in general payments reported to CMS, 2019-2025
36 companies · $2,459 in 2025
The $2,459 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $259 · 2021: $744 · 2022: $801 · 2023: $1,852 · 2024: $2,289 · 2025: $2,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,400 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,400.49 |
| Education | $199.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $889.09 | 2020-2025 | Opdivo, Reblozyl, Opdualag |
| Pbg Puerto Rico LLC | $888.54 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $801.40 | 2021-2025 | Lynparza, Tagrisso, Imfinzi |
| Merck Sharp & Dohme LLC | $785.54 | 2021-2025 | Keytruda, Welireg, Keytruda Qlex |
| Janssen Pharmaceuticals, INC | $749.20 | 2019-2025 | Darzalex, Erleada, Rybrevant |
| Amgen INC. | $528.03 | 2021-2025 | Xgeva, Lumakras, Kyprolis |
| Abbvie INC. | $516.28 | 2019-2025 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $488.90 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $475.68 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $378.45 | 2019-2025 | |
| Genentech USA, INC. | $347.83 | 2019-2024 | Lunsumio, Polivy, Perjeta |
| Seagen INC. | $226.43 | 2022-2025 | Tukysa |
| Puma Biotechnology, INC. | $190.81 | 2020-2025 | |
| Astellas Pharma US INC | $180.07 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $168.53 | 2020-2025 | Ninlaro |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $121.88 | 2024-2025 | Libtayo, Lynozyfic |
| Sanofi-Aventis U.S. LLC | $121.51 | 2021-2023 | |
| Bayer Puerto Rico INC. | $112.66 | 2024-2025 | Nubeqa, Stivarga, Vitrakvi |
| Caris Mpi, INC. | $105.70 | 2025 | Mi Cancer Seek |
| Sobi, INC | $88.55 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.26 | 2021-2022 | |
| Incyte Corporation | $77.15 | 2019-2020 | |
| Janssen Biotech, INC. | $64.99 | 2021 | |
| Gilead Sciences, INC. | $64.22 | 2023-2025 | Trodelvy |
| Tempus Ai, INC | $53.83 | 2024-2025 | Xt Cdx |
| Taiho Oncology, INC. | $51.04 | 2022 | |
| Telix Pharmaceuticals | $50.17 | 2025 | Illuccix |
| Pfizer INC. | $43.09 | 2021-2022 | |
| Eisai INC. | $42.24 | 2019-2021 | |
| Exelixis INC. | $36.64 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $26.08 | 2020 | |
| Emd Serono, INC. | $25.00 | 2023 | Bavencio |
| Global Blood Therapeutics, INC. | $24.00 | 2022 | |
| Morphosys, US INC. | $22.45 | 2022 | |
| Kyowa Kirin, INC. | $22.45 | 2022 | |
| Beigene USA, INC. | $16.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalia Almodovar Arbelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.